Robert Langer
About Robert Langer
Robert Langer is an Institute Professor at MIT. He is a co-founder of Moderna. Press coverage describes him as having founded more than 40 spinouts and holding more than 1,500 patents.
His company-building work is mostly in biotech and drug delivery. PitchBook lists him as a co-founder of PureTech Health, Pulmatrix, Acusphere, PixarBio, TISSIUM and Verseau, among others. It also lists board or advisory roles at Seer, Immunai and Abpro Therapeutics.
He is also executive chair of T.Rx Capital, a venture firm co-founded with his son Michael Langer. Crunchbase lists him as founder of Soufflé Therapeutics.
Public records of his personal angel investments are thin. PitchBook shows two: Luminopia (March 2020, therapeutic devices) and Cheiron (2026 seed round). Crunchbase shows one personal investment, in Cheiron.
Most of his public activity is as a founder, board member or scientific advisor, not as a check-writing angel. Investment amounts for his personal deals are not public.
Cheiron is his one confirmed AI investment. Cheiron is a Los Altos, California startup building an AI-native operating system for drug development programs. It raised an $8M seed round led by Menlo Ventures in July 2026.
Press releases name Langer among the strategic backers. Other backers named include Freda Lewis-Hall, John Giannandrea and Chai Discovery CEO Josh Meier. Langer is also listed as one of Cheiron's advisors. PitchBook describes him as an advisor at Cheiron, and lists him as an advisor or board member at Immunai, which is an AI-related company.
His public work centers on life sciences and the point where biology meets technology. For T.Rx Capital, the firm says it backs founders at that intersection. Its $77.5M first fund targets company creation through Series B, aiming for 10 to 15 portfolio companies with checks of $5M to $10M. Those figures describe the fund, not Langer's personal angel checks.
No personal check size, stage preference or stated pitch criteria for his angel investing are public. The evidence suggests he prefers companies where he can also advise on science and product direction.
- Cheiron: AI-native operating system for drug development programs; $8M seed led by Menlo Ventures, July 2026. Langer is an investor and advisor.
- Luminopia: therapeutic devices company; PitchBook records a 2020 investment.
- T.Rx Capital: venture firm where Langer is executive chair; $77.5M first fund (a fund role, not a personal angel investment).
- hitconsultant.net/2026/07/22/cheiron-raises-8m-seed-menlo-ventures-dru
- thepharmaletter.com/pharma-news/cheiron-lands-8-million-seed-to-turn-t
- app.dealroom.co/news/note/cheiron-raises-8m-seed-led-by-menlo-ventures
- tipranks.com/news/private-companies/cheiron-raises-8-million-to-build-
- pitchbook.com/profiles/investor/510731-02
- crunchbase.com/person/robert-s-langer
- fiercebiotech.com/biotech/moderna-co-founder-robert-langers-son-launch
- thenextleap.is/news/trx-capital-fund-i
Investing activity
Robert Langer appears in 1 AI deal tracked by the Lounge deals desk. The rounds are mostly Seed, with a median round size of $8M. The most recent is Cheiron (Seed, $8M, Jul 2026).
Robert Langer most often invests alongside Menlo Ventures, Josh Meier, Laxman Narasimhan and Freda Lewis-Hall, and the companies they back on Lounge are mostly in AI.
Deals
Frequently asked questions about Robert Langer
Does Robert Langer invest in AI startups?
Yes, at least in drug development AI. He backed Cheiron's $8M seed round in July 2026 and is listed as an advisor to the company.
What is Robert Langer's angel check size?
His personal check size is not public. The $5M to $10M range in public reporting applies to his T.Rx Capital fund, not to his angel investing.
What stage does Robert Langer invest in?
His confirmed AI deal is a seed round. T.Rx Capital's stated range runs from company creation through Series B.
What sectors does Robert Langer back?
Mainly life sciences, biotech and the overlap of biology and technology. Cheiron applies AI to biopharma drug development.
Who is Robert Langer?
He is an MIT Institute Professor and Moderna co-founder. He has co-founded dozens of companies and is executive chair of T.Rx Capital.
Should I pitch Robert Langer if I am not in life sciences?
His public record is almost entirely in life sciences and biotech. A pitch is most relevant if you apply AI to drug discovery, development or biopharma operations.
Is Robert Langer an angel investor?
Yes. Robert Langer invests personally as an angel.
What AI companies has Robert Langer invested in?
Robert Langer's AI investments include Cheiron. The 1 round on Lounge are listed on this page with amounts, dates and co-investors.
What stage does Robert Langer invest at?
In the rounds tracked on Lounge, Robert Langer has invested at Seed, with a median round of $8M.
Who does Robert Langer co-invest with?
Robert Langer's most frequent co-investors on Lounge are Menlo Ventures (1 deal), Josh Meier (1 deal), Laxman Narasimhan (1 deal), Freda Lewis-Hall (1 deal) and John Giannandrea (1 deal).